Announcement on Voluntarily Disclosure of Obtaining FDA Approval for Phase I/II Clinical Trial Application of HP537 Tablets in the Treatment of Hematologic Malignancies

About this update from Hinova Pharmaceuticals, Inc. Class A

Announcement on Voluntarily Disclosure of Obtaining FDA Approval for Phase I/II Clinical Trial Application of HP537 Tablets in the Treatment of Hematologic Malignancies The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Hinova Pharmaceuticals, Inc. Class A